Skip to main content
Clinical Trials/NCT05805683
NCT05805683
Recruiting
Not Applicable

Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury

Tanta University1 site in 1 country50 target enrollmentMay 1, 2023

Overview

Phase
Not Applicable
Intervention
Calcitonin
Conditions
Calcitonin
Sponsor
Tanta University
Enrollment
50
Locations
1
Primary Endpoint
Intensity of neuropathic pain
Status
Recruiting
Last Updated
12 months ago

Overview

Brief Summary

This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury

Detailed Description

Pain after spinal cord injury can be classified into five categories: musculoskeletal, visceral, at-level, above-level, and below-level neuropathic pain. Calcitonin has previously been shown to be effective in the management of acute pain following amputation, vertebral fractures and other neuropathic conditions. Also it was used in a previous study to prevent complex regional pain syndrome in severe hemiplegic patients after stroke

Registry
clinicaltrials.gov
Start Date
May 1, 2023
End Date
May 1, 2027
Last Updated
12 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Osama Rehab

lecturer of anesthesiology, surgical intensive care and pain medicine Tanta university

Tanta University

Eligibility Criteria

Inclusion Criteria

  • Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.

Exclusion Criteria

  • Intake of anticonvulsants medications.
  • Evidence of neuropathic pain.
  • Evidence of previous allergic reaction to calcitonin.
  • Patients with renal, hepatic and cardiac dysfunction or neurological disorders .
  • brain damage or major trauma to extremities or abdomen.

Arms & Interventions

Calcitonin group

patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.

Intervention: Calcitonin

Placebo group

patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.

Intervention: Placebo

Outcomes

Primary Outcomes

Intensity of neuropathic pain

Time Frame: 6 months after spinal cord injury

Intensity of neuropathic pain will be evaluated by visual analogue scale (VAS) scores within the 1st 6 months after spinal cord injury

Incidence of chronic pain

Time Frame: 12 months after spinal cord injury

Incidence of chronic pain at 12 months after spinal cord injury

Secondary Outcomes

  • Intensity of nociceptive pain(12 months after spinal cord injury)
  • Incidence of neuropathic pain(12 months after spinal cord injury)
  • The incidence of adverse reactions(2 weeks after spinal cord injury)
  • The consumption of medications for neuropathic pain or musculoskeletal pain(12 months after spinal cord injury)
  • Intensity of neuropathic pain(12 months after spinal cord injury)

Study Sites (1)

Loading locations...

Similar Trials